Licensing Opportunities


Office of Technology Transfer 


Project TitleCombination Therapy for Cancer – Oral Fenretinide and Microtubule inhibitors
Track Code2006-003
Short Description

Tech Summary:  This invention combines fenretinide with microtubule inhibitors to increase the therapeutic effect of fenretinide as an anti-cancer drug.


Technology Summary: Combines fenretinide with microtubule inhibitors to increase its therapeutic effect as an anti-cancer drug.

This invention is related to Fenretinide (4-hydroxy(phenyl) retinamide), a synthetic retinoid derivative that has been investigated for potential use in the treatment of cancer and some other diseases, such as macular degeneration.  Specific types of cancer investigated include bladder, breast, Non-Hodgkin's lymphoma, neuroblastoma, and Ewing's sarcoma

Bioavailability of the long-established fenretinide formulation has been a limiting factor in achieving optimal therapeutic benefit.

Technology Description: 
This invention proposes the use of fenretinide, a well known anticancer agent, in combination with microtubule inhibitors. These inhibitors are another important class of anti-cancer agents.

Pre-clinical data from multiple tumor xenograft models show that fenretinide is more effective when used with microtubule inhibitors instead of as a single agent.

The combination of fenretinide and microtubule inhibitors is well-tolerated in mice. Its synergistic effect presents a novel treatment approach in oncology.

Kang MH, Wan Z, Kang YH, Sposto R, Reynolds CP (2008). Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation. J Natl Cancer Inst. 2008 Apr 16;100(8):580-95.          


  • Cancer treatment
  • Macular degeneration


  • Orally administered
  • Improved bioavailability
  • Improved anti-tumor activity of fenretinide

Development Stage:
 Pre-clinical proof of principle data.

IP Protection: PCT application filed PCT/US2007/011686

Tagsanti-cancer, anti-cancer therapy, anticancer, anticancer agents, drug formulation, fenretinide, inhibitors, oncology, oncology drugs, retinoid acid, retinoid acid derivatives, solid tumor, therapeutic, therapeutic agents, therapeutic compound, therapy, tumor treatments, microtubule inhibitor, bladder cancer, breast cancer, non-hodgkin's lymphoma, neuroblastoma, Ewing's sarcoma.
Posted DateOct 26, 2010 4:59 PM


C. Patrick Reynolds
Barry J Maurer

Intellectual Property

Patent Number Issue Date Type Country of Filing
PCT/US2007/011686 May 16, 2007 Other Patent United States